查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401866

到 2030 年毒蕈鹼乙醯膽鹼受體的全球市場預測：按類型、產品、配銷通路、應用、最終用戶和地區進行分析

Muscarinic Acetylcholine Receptor Market Forecasts to 2030 - Global Analysis By Type (M1, M4, M5 and Other Types), Product (Tropicamide, Nu-0467154, Anauex-273 and Other Products), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球毒蕈鹼乙醯膽鹼受體市場規模為 17.5 億美元，預計在預測期內複合年成長率為 6.9%，到 2030 年將達到 27.9 億美元。

毒蕈鹼乙醯膽鹼受體是一類可以抑制突觸後神經元並參與多種週邊和中樞活動的控制的受體。它負責調節副交感神經系統的生理後果。它具有抑制和興奮作用，可以阻斷或刺激反應，並作為膽鹼能神經元儲存在產生乙醯膽鹼的神經元中。

據支持醫學研究的美國非營利組織美國心臟協會稱，到 2060 年，美國患有阿茲海默症和相關失智症的人數預計將增加到 930 萬人。

神經系統疾病盛行率增加

由於人口高齡化和生活方式的改變，阿茲海默症、帕金森氏症和思覺失調症等神經系統疾病變得越來越普遍。毒蕈鹼乙醯膽鹼受體在這些疾病中發揮重要作用，並且是藥物開發的有吸引力的標靶。此外，由於迫切需要解決醫療保健系統中神經系統疾病的負擔以及對創新治療方法的需求不斷成長，市場正在擴大。這為該領域的製藥公司和研究人員提供了巨大的潛力，也為患者帶來了潛在的希望。

副作用和安全問題

針對毒蕈鹼乙醯膽鹼受體的藥物可能會引起口乾、視力模糊、便秘、頭暈和認知障礙等副作用。這些副作用會影響患者的依從性和生活品質，尤其是老年人群，他們可能已經因老齡化相關問題而出現這些症狀。平衡治療效果和副作用可能很困難，並且限制了患者的醫囑遵從性。還有安全性問題，因為它可能會影響心血管和呼吸系統。結果，它阻礙了市場的擴張。

標靶治療

標靶治療可以提供更精確的治療選擇、最大限度地減少副作用並改善治療結果。根據每個患者的受體特徵客製化干涉措施可以使個人化醫療成為現實，並徹底改變阿茲海默症、思覺失調症和帕金森氏症等疾病的治療方法。此外，藥物傳遞系統和診斷工具的進步可以最佳化這些治療的功效。這為製藥公司和研究人員開發創新的、以患者為中心的解決方案並推動市場成長提供了一條充滿希望​​的道路。

監管障礙

開發針對毒蕈鹼受體的藥物需要遵守嚴格的監管要求，包括廣泛的臨床試驗和安全性評估。此類要求會延長開發時間、增加成本並帶來監管脫軌的風險。延誤和拒絕阻礙了市場進入並阻礙了製藥公司。這些障礙可能會抑制創新，延遲神經和精神疾病新治療方法的推出，並影響市場成長和競爭。

COVID-19 的影響

COVID-19 的爆發嚴重影響了肌肉乙醯膽鹼受體市場。由於供應鏈中斷、研發業務受到限制以及醫療資源的重新調整，臨床試驗和藥物開發正在推遲。此外，由於對遠距醫療的重視和親自就診的減少，患者獲得毒蕈鹼受體相關藥物的機會受到影響。然而，這場大流行凸顯了神經學研究和創新的重要性，隨著醫療保健系統適應未來的挑戰和機遇，也可能增加對該市場的興趣和投資。

托吡卡胺產業預計將在預測期內成為最大的產業

預計托吡卡胺領域將佔最大佔有率。托吡卡胺是一種藥物，屬於抗膽鹼能藥物或毒蕈鹼拮抗類藥物。在眼科領域主要用作環丁二烯促效劑和散瞳劑。透過抑制虹膜和睫狀肌中的毒蕈鹼乙醯膽鹼受體，托吡卡胺麻痺眼睛的聚焦肌肉並導致瞳孔擴張。托吡卡胺在眼科領域的應用強調了它與更大市場的聯繫，該市場包括針對這些受體的藥物和治療方法，以治療各種疾病，包括精神疾病和神經系統疾病。

預計精神疾病產業在預測期內複合年成長率最高

預計精神疾病領域在預測期內將出現良好成長。毒蕈鹼乙醯膽鹼受體是一組存在於中樞神經系統中的受體，在調節多種腦部功能中發揮重要作用。這些受體的功能障礙與多種精神疾病有關，包括思覺失調症、躁鬱症和重度憂鬱症。該市場專注於能夠為精神疾病患者提供更有效、更有針對性的治療的創新治療方法，使其成為醫療進步的一個有前途的途徑。因此，該領域的需求預計將會增加。

佔有率最大的地區

由於醫療保健支出增加和老年人口增加，亞太地區在預測期內獲得了最大的市場佔有率。該市場包括與毒蕈鹼乙醯膽鹼受體（神經系統的重要組成部分）相關的藥品、研究工具和診斷產品。該市場受到神經系統疾病的流行、藥物開發的進步以及神經系統研究的增加等因素的影響。此外，該地區的主要製藥公司、研究機構和生物技術公司正在致力於開發和商業化與這些受體相關的產品。學術界和工業界之間的合作很常見，精準醫療方法和標靶治療是主要趨勢，反映出該地區對個人化醫療解決方案的日益關注。

複合年成長率最高的地區：

由於成熟的醫療基礎設施、高研發投資和大量患者人口，預計北美在預測期內將出現有益成長。市場規模受到與這些受體相關的疾病的流行、藥物開發的進展以及神經病學和相關領域的研究等因素的影響。此外，製藥公司正在開發針對多種醫療狀況的毒蕈鹼乙醯膽鹼受體的藥物，包括阿茲海默症神經系統疾病。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球毒蕈鹼乙醯膽鹼受體市場：依類型

  • 介紹
  • M1
  • M4
  • M5
  • 其他類型

第6章全球毒蕈鹼乙醯膽鹼受體市場：依產品

  • 介紹
  • 托吡卡胺
  • Nu-0467154
  • Anauex-273
  • 其他產品

第7章全球毒蕈鹼乙醯膽鹼受體市場：按配銷通路

  • 介紹
  • 零售藥房
  • 專賣店
  • 線上藥房

第8章全球毒蕈鹼乙醯膽鹼受體市場：依應用分類

  • 介紹
  • 慢性阻塞性肺病
  • 阿茲海默氏症
  • 精神疾病
  • 注意力不足過動症
  • 記憶障礙

第9章全球毒蕈鹼乙醯膽鹼受體市場：依最終用戶分類

  • 介紹
  • 製藥公司
  • 醫療設施
  • 研究機構
  • 診斷中心

第10章全球毒蕈鹼乙醯膽鹼受體市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • AstraZeneca
  • Anavex Life Sciences Corp.
  • Sosei Heptares.
  • Karuna Therapeutics.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • NeuroHealing Pharmaceuticals Inc.
  • Heptares Therapeutics Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Johnson & Johnson
  • Boehringer Ingelheim International Gmbh
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Ltd
  • Merck & Co., Inc
  • AbbVie Inc.
  • Elsevier BV
  • Eurofins DiscoverX Corporation
  • Novus Biologicals
Product Code: SMRC24386

According to Stratistics MRC, the Global Muscarinic Acetylcholine Receptor Market is accounted for $1.75 billion in 2023 and is expected to reach $2.79 billion by 2030 growing at a CAGR of 6.9% during the forecast period. Muscarinic acetylcholine receptors are a class of receptors that can inhibit postsynaptic neurons and are involved in the regulation of several peripheral and central activities. They are responsible for regulating the parasympathetic nervous system's physiological consequences. It has both inhibitory and excitatory effects that can block or stimulate the response and is stored in the acetylcholine-producing neurons as cholinergic neurons.

According to the American Heart Association, a US-based nonprofit organization that supports medical research, the number of persons affected by Alzheimer's disease and associated dementias in the United States is expected to rise to 9.3 million by 2060.

Market Dynamics:

Driver:

Increasing prevalence of neurological disorders

Neurological conditions, such as Alzheimer's disease, Parkinson's disease, and schizophrenia, are becoming more widespread due to ageing populations and changing lifestyles. Muscarinic acetylcholine receptors play a crucial role in these disorders, making them attractive targets for drug development. Moreover, the market is growing as a result of a dire need to address the burden of neurological illnesses on healthcare systems and the growing need for innovative therapies. This presents both significant possibilities for pharmaceutical companies and researchers in the field, as well as potential hope for patients.

Restraint:

Side effects and safety concerns

Medications targeting muscarinic acetylcholine receptors can lead to adverse effects such as dry mouth, blurred vision, constipation, dizziness, and cognitive impairment. These side effects can impact patient compliance and quality of life, particularly in elderly populations that may already experience some of these symptoms due to age-related issues. Balancing therapeutic benefits with side effects is challenging, potentially limiting patient adherence. Safety concerns also arise due to the potential impact on cardiovascular and respiratory systems. Thus, they are limiting market expansion.

Opportunity:

Targeted therapies

Targeted therapies can offer more precise treatment options, minimising side effects and enhancing therapeutic outcomes. By tailoring interventions to the individual patient's receptor profile, personalised medicine becomes a reality, potentially revolutionising the treatment of conditions like Alzheimer's disease, schizophrenia, and Parkinson's disease. Furthermore, advancements in drug delivery systems and diagnostic tools can optimise the effectiveness of these therapies. This presents a promising avenue for pharmaceutical companies and researchers to develop innovative, patient-centric solutions and drive growth in the market.

Threat:

Regulatory hurdles

Developing drugs targeting muscarinic receptors requires adherence to rigorous regulatory requirements, including extensive clinical trials and safety assessments. These demands lead to extended timelines, increased costs, and the risk of regulatory setbacks. Delays or rejections can hinder market entry and deter pharmaceutical companies. These obstacles may impede innovation, potentially delaying the availability of new treatments for neurological and psychiatric disorders and impacting the market's growth and competitiveness.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the muscle acetylcholine receptor market. Clinical trial and medication development have been delayed as a result of supply chain interruptions, limitations imposed on research and development operations, and the reorganisation of healthcare resources. Additionally, patient access to muscarinic receptor-related medicines was impacted by the emphasis on telehealth and the decline in in-person healthcare visits. However, the pandemic also underscored the importance of neurological research and innovation, potentially driving increased interest and investment in this market as healthcare systems adapt to future challenges and opportunities.

The Tropicamide segment is expected to be the largest during the forecast period

The Tropicamide segment is estimated to hold the largest share. Tropicamide is a pharmaceutical medication that belongs to a class of drugs known as anticholinergics or muscarinic antagonists. In ophthalmology, it is mainly employed as a cycloplegic and mydriatic agent. Tropicamide works by paralysing the focusing muscle of the eye and dilatation of the pupil by inhibiting muscarinic acetylcholine receptors in the iris and ciliary muscle. The application of tropicamide in ophthalmology highlights its connection to the larger market, which includes medications and treatments that target these receptors to treat a range of illnesses, including psychological and neurological diseases.

The Psychiatric Disorders segment is expected to have the highest CAGR during the forecast period

The Psychiatric Disorders segment is anticipated to have lucrative growth during the forecast period. Muscarinic acetylcholine receptors are a group of receptors in the central nervous system that play a crucial role in regulating various brain functions. Dysfunction in these receptors is implicated in several psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. This segment of the market focuses on innovative therapies that can offer more effective and targeted treatments for individuals suffering from psychiatric conditions, representing a promising avenue for medical advancements. Hence, this will propel segment demand.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising healthcare expenditures and a growing geriatric population. It encompasses pharmaceuticals, research tools, and diagnostics associated with muscarinic acetylcholine receptors, vital components in the nervous system. This market is influenced by factors such as the prevalence of neurological disorders, advancing drug development, and increasing research in neurology. Moreover, major pharmaceutical companies, research institutions, and biotechnology firms in the region engage in the development and commercialization of products related to these receptors. Collaborations between academia and industry are common, and precision medicine approaches and targeted therapies are key trends, reflecting a growing focus on personalised healthcare solutions in the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the presence of a well-established healthcare infrastructure, high research and development investments, and a large patient population. The market size is influenced by factors such as the prevalence of conditions related to these receptors, advancements in drug development, and research in neurology and related fields. Furthermore, pharmaceutical companies develop drugs targeting muscarinic acetylcholine receptors for various medical conditions, including neurological disorders like Alzheimer's disease.

Key players in the market:

Some of the key players in the Muscarinic Acetylcholine Receptor Market include AstraZeneca, Anavex Life Sciences Corp., Sosei Heptares, Karuna Therapeutics, Sumitomo Dainippon Pharma Co., Ltd., NeuroHealing Pharmaceuticals Inc., Heptares Therapeutics Ltd., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Boehringer Ingelheim International Gmbh, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Merck & Co., Inc, AbbVie Inc., Elsevier B.V., Eurofins DiscoverX Corporation and Novus Biologicals.

Key Developments:

In November 2023, AstraZeneca announces multi-year partnership with NHL and NHLPA Hockey Fights Cancer initiative. Through this multi-year partnership, AstraZeneca, the NHLPA, and the NHL will leverage the Hockey Fights Cancer platform to encourage fans to win at their own G.A.M.E: Gauge risk factors, Arrange a screening, make a donation, Educate loved ones.

In July 2023, AstraZeneca India strengthens partnership with SASTRA University. The collaboration between AstraZeneca and SASTRA University aims to strengthen industry-academia ties and equip students with expertise in various aspects of clinical research.

In June 2023, AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.

Types Covered:

  • M1
  • M4
  • M5
  • Other Types

Products Covered:

  • Tropicamide
  • Nu-0467154
  • Anauex-273
  • Other Products

Distribution Channels Covered:

  • Retail Pharmacies
  • Speciality Stores
  • Online Pharmacies

Applications Covered:

  • Chronic Obstructive Pulmonary Disease
  • Alzeheimers Disease
  • Psychiatric Disorders
  • Attention Deficit Hyperactivity Disorder
  • Memory Impairment

End Users Covered:

  • Pharmaceutical Companies
  • Healthcare Facilities
  • Research Institutes
  • Diagnostic Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Muscarinic Acetylcholine Receptor Market, By Type

  • 5.1 Introduction
  • 5.2 M1
  • 5.3 M4
  • 5.4 M5
  • 5.5 Other Types

6 Global Muscarinic Acetylcholine Receptor Market, By Product

  • 6.1 Introduction
  • 6.2 Tropicamide
  • 6.3 Nu-0467154
  • 6.4 Anauex-273
  • 6.5 Other Products

7 Global Muscarinic Acetylcholine Receptor Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Speciality Stores
  • 7.4 Online Pharmacies

8 Global Muscarinic Acetylcholine Receptor Market, By Application

  • 8.1 Introduction
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Alzeheimers Disease
  • 8.4 Psychiatric Disorders
  • 8.5 Attention Deficit Hyperactivity Disorder
  • 8.6 Memory Impairment

9 Global Muscarinic Acetylcholine Receptor Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Healthcare Facilities
  • 9.4 Research Institutes
  • 9.5 Diagnostic Centers

10 Global Muscarinic Acetylcholine Receptor Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 Anavex Life Sciences Corp.
  • 12.3 Sosei Heptares.
  • 12.4 Karuna Therapeutics.
  • 12.5 Sumitomo Dainippon Pharma Co., Ltd.
  • 12.6 NeuroHealing Pharmaceuticals Inc.
  • 12.7 Heptares Therapeutics Ltd.
  • 12.8 Pfizer Inc.
  • 12.9 GlaxoSmithKline plc
  • 12.10 Novartis AG
  • 12.11 Johnson & Johnson
  • 12.12 Boehringer Ingelheim International Gmbh
  • 12.13 Eli Lilly and Company
  • 12.14 Takeda Pharmaceutical Company Ltd
  • 12.15 Merck & Co., Inc
  • 12.16 AbbVie Inc.
  • 12.17 Elsevier B.V.
  • 12.18 Eurofins DiscoverX Corporation
  • 12.19 Novus Biologicals

List of Tables

  • Table 1 Global Muscarinic Acetylcholine Receptor Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 4 Global Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 5 Global Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 6 Global Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 8 Global Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 9 Global Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 10 Global Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 11 Global Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 12 Global Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 15 Global Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 16 Global Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 18 Global Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 19 Global Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 20 Global Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 21 Global Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 22 Global Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 24 Global Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 25 Global Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 26 Global Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 27 North America Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 29 North America Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 30 North America Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 31 North America Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 32 North America Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 33 North America Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 34 North America Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 35 North America Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 36 North America Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 37 North America Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 38 North America Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 39 North America Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 40 North America Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 41 North America Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 North America Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 North America Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 44 North America Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 45 North America Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 46 North America Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 47 North America Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 48 North America Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 50 North America Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 51 North America Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 52 North America Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 53 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 55 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 56 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 57 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 58 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 59 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 61 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 62 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 63 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 64 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 65 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 66 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 67 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 68 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 69 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 70 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 71 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 72 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 73 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 74 Europe Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 76 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 77 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 78 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 79 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 82 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 83 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 84 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 85 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 86 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 87 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 88 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 89 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 90 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 91 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 92 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 93 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 94 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 95 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 96 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 97 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 98 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 99 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 100 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 102 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 103 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 104 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 105 South America Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 107 South America Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 108 South America Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 109 South America Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 110 South America Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 111 South America Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 112 South America Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 113 South America Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 114 South America Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 115 South America Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 116 South America Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 117 South America Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 118 South America Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 119 South America Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 120 South America Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 121 South America Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 122 South America Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 123 South America Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 124 South America Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 125 South America Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 126 South America Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 128 South America Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 129 South America Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 130 South America Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 131 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 134 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 135 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 136 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 137 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 138 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 139 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 140 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 141 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 142 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 143 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 144 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 145 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 146 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 147 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 148 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 149 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 150 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 151 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 152 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 154 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 155 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 156 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)